Combination of α-CTLA-4 and α-PD-L1 mAb treatment resulted in complete control of metastatic osteosarcoma tumors with long-term disease-free survival in roughly 60% of α-CTLA-4 + α-PD-L1 mAb treated mice. This evidence concerns the gene CTLA4 and osteosarcoma.